News
2024
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
– Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S. – – Announced approval of an IDE…
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel, and Miami, FL — November 4, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the…
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
Miami, Florida — October 15, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of…
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
Miami, Florida — October 7, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S….
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS…
New! Mullings Group Interview with InspireMD Leadership
Dear Investors, We are pleased to share with you an exciting development that highlights our continued success and promising future. Recently, Joe Mullings, Chairman & CEO of the Mullings Group…
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
– Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any…
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard Tel Aviv, Israel, and Miami, Florida — Augst…
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th -Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv,…
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind,…
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket…
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
– Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 – – Announced that an abstract detailing one-year outcomes…
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel, and Miami, FL — May 7, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the…
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
Tel Aviv, Israel, and Miami, Florida — April 3, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today…
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
Tel Aviv, Israel, and Miami, Florida — March 26, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today…
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
– Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 – – Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device…
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel, and Miami, FL — February 28, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™…
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and platform Tel Aviv, Israel,…
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
Tel Aviv, Israel, and Miami, FL — January 31, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke,…
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4) Tel Aviv, Israel,…
2023
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuardTM Neuroprotection System
Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the…
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
Study to enroll 15 acute stroke patients across three U.S. sites. Tel Aviv, Israel, and Miami, Florida — November 27, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™…
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update – Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall…
InspireMD to Participate in Upcoming November Investor Conferences
Tel Aviv, Israel, and Miami, FL — November 2, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and…
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure. Tel Aviv, Israel, and Miami, Florida — November 1, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer…
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel, and Miami, FL — October 30, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™…
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid endarterectomy) to minimally invasive CAS and…
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs Shane Gleason, current General Manager…
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
Tel Aviv, Israel, and Miami, Florida — August 31, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today…
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – – Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and…
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company anticipates…
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Tel Aviv, Israel and Miami, Florida — May 18, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today…
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – – Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over…
InspireMD Announces Private Placement of Up to $113.6 Million
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants…
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel— May 12, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent…
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel— May 5, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention…
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system. CGuardians enrollment on…
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
Tel Aviv, Israel— April 27, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke…
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
– 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 – – Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD)…
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St….
InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel— March 2, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System…
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing Tel Aviv, Israel — February 14, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer…
2022
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists
Series to feature leading experts discussing the current and future trends in the carotid treatment market Tel Aviv, Israel — November 28, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer…
InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet™ Mesh Covering at the 2022 VEITH Symposium
Tel Aviv, Israel — November 15, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company…
InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
– Generated 38.8% growth in CGuard™ revenue year-over-year – – Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by…
InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel— October 25, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System…
InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference
Tel Aviv, Israel — September 13, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company…
NAMSA AND INSPIREMD ANNOUNCE STRATEGIC OUTSOURCING PARTNERSHIP TO ACCELERATE NEW PRODUCT DEVELOPMENT
TOLEDO, OHIO and TEL AVIV, ISRAEL – BUSINESSWIRE—SEPTEMBER 8, 2022—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the…
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update
– Generated 47.8% growth in CGuard™ revenue year-over-year – – Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission – – Announced that endovascular…
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update
-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel— August 1, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System…
InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor
Credited with performing the first ever endovascular repair procedure in 1990 Tel Aviv, Israel — July 14, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System…
InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022
Successful live case transmission again demonstrated CGuard’s™ differentiated patient protection features and ease of use Tel Aviv, Israel — June 9, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the…
InspireMD’s CGuard™ Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022
Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of CGuard™ Embolic Prevention System (EPS) Tel Aviv, Israel — June 2, 2022 – InspireMD, Inc. (Nasdaq: NSPR),…
InspireMD Reports First Quarter 2022 Financial Results and Business Update
– 20% growth in CGuard™ revenue Year-over-Year – – C-Guardian FDA IDE Trial Completes First European Enrollment – – Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and…
InspireMD to Report First Quarter 2022 Financial Results on May 10, 2022 and Provide Corporate Business Update
-Earnings Conference Call to be held Tuesday, May 10, 2022, at 8:30 a.m. ET- Tel Aviv, Israel— April 28, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic…
InspireMD to Host Key Opinion Leader Event on Carotid Artery Disease Management and Stroke Prevention in combination with the CGuard™ Stent Platform & MicroNet™ Portfolio
Tuesday, March 22nd @ 2 p.m. ET Tel Aviv, Israel— March 16, 2022 – InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for…
InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results
– CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- – Published CGuard Clinical trial results in Journals of the American College of Cardiology – – Established Reimbursement…
InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application
– CGuard™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients – – CREST-2 Trial is sponsored by the…
InspireMD to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 and Provide Corporate Business Update
-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- Tel Aviv, Israel— February 22, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic…
InspireMD Announces Adnan Siddiqui, MD, PhD as a Member of its Scientific Advisory Board and Strategic Advisor
Dr. Siddiqui is recognized for his extensive experience in Microsurgical, Radiosurgical and Endovascular Techniques for the Comprehensive Management of Vascular Disease Tel Aviv, Israel— February 15, 2022 – InspireMD, Inc. (Nasdaq:…
InspireMD to Present at the 16th Biennial Scientific Meeting of the International Andreas Gruentzig Society (IAGS) – Biennial Scientific Meeting of the IAGS to be held from January 31st – February 3rd 2022 –
Tel Aviv, Israel— January 27, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today…
InspireMD Announces Live Case Broadcast at ISET 2022 Conference Following the Supplement Approval by the FDA Regarding its Pivotal C-Guardians Trial
– Live Case will be Broadcasted Today at 11:00am ET – Tel Aviv, Israel— January 18, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS)…
2021
InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- -$37.1 million in cash, cash…
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions
Tel Aviv, Israel— November 3, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery…
InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update -Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET-
Tel Aviv, Israel— October 26, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and…
InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health
Tel Aviv, Israel— October 13, 2021 – InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease…
InspireMD Announces Strong Second Quarter 2021 Financial Results
Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET Tel Aviv, Israel— August 10, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of…
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS
Tel Aviv, Israel— July 23, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and…
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
Tel Aviv, Israel— June 2, 2021 – InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced…
InspireMD Commences Trading on Nasdaq-CM
Ticker to remain NSPR Tel Aviv, Israel— May 21, 2021 – InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused…
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021
Tel Aviv, Israel— May 14, 2021 – InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid…
InspireMD Announces Appointment of Katie Arnold to Board of Directors
Tel Aviv, Israel – May 12, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment…
InspireMD Announces First Quarter 2021 Financial Results
Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021 Management to host investor conference call today, May 11, 2021, at 8:30am ET Tel Aviv, Israel—…
InspireMD Announces Stock Exchange Listing Transfer to Nasdaq
Ticker to remain NSPR Tel Aviv, Israel— May 10, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused…
InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021
Tel Aviv, Israel— May 6, 2021 – InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid…
InspireMD to Report First Quarter 2021 Financial Results on Tuesday, May 11, 2021 and Provide Corporate Update
Earnings conference call to be held Tuesday, May 11, 2021 at 8:30 a.m. ET Tel Aviv, Israel — May 4, 2021 – InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the…
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
Tel Aviv, Israel – April 29, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid…
InspireMD Provides Corporate Update for Shareholders
Tel Aviv, Israel— April 19, 2021 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the…
InspireMD Announces 1-for-15 Reverse Stock Split
Tel Aviv, Israel— April 14, 2021 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the…
InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders
Tel Aviv, Israel – March 22, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid…
We Are Contacting You as a Reminder of a Critical Shareholder Vote. InspireMD Inc. Urges Shareholders to Vote FOR Reverse Stock Split Proposal
VOTE NOW BY CALLING KINGSDALE ADVISORS AT 1-866-581-1479.or collect at 1-416-867-2272 AND ONE OF OUR AGENTS WOULD BE HAPPY TO TAKE YOUR VOTE OVER THE PHONE. Dear InspireMD Inc. (NSPR)…
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
Management to host investor conference call today, March 9, at 8:30am ET Tel Aviv, Israel— March 9, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention…
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Tel Aviv, Israel — March 2, 2021 – InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or…
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
Tel Aviv, Israel – February 24, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery…
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
Tel Aviv, Israel – February 9, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid…
INSPIREMD ANNOUNCES CLOSING OF AN UPSIZED $20.7 MILLION UNDERWRITTEN PUBLIC OFFERING AND FULL EXERCISE OF OVER-ALLOTMENT OPTION
Tel Aviv, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet™ stent platform technology for…
INSPIREMD ANNOUNCES PRICING OF UPSIZED $18 MILLION UNDERWRITTEN PUBLIC OFFERING
Tel Aviv, Israel / February 4, 2021 / InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet™ stent platform technology for the treatment…
InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China
New Chinese Distributor Will Also Invest in At-The-Market Private Placement Tel Aviv, Israel – February 3, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention…
InspireMD’s CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021
Tel Aviv, Israel – January 26, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid…
2020
InspireMD Announces Third Quarter 2020 Financial Results
Third quarter 2020 revenue returns to pre-COVID-19 levels Management to host investor conference call today, November 9, 2020 at 8:30 a.m. ET Tel Aviv, Israel— November 9, 2020 –…
InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)
Tel Aviv, Israel – November 3, 2020 – InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by…
InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update
Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Tel Aviv, Israel — November 2, 2020 – InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the…
InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors
Tel Aviv, Israel — October 13, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid…
InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)
Tel Aviv, Israel – October 6, 2020 – InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by…
InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System
Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Tel Aviv, Israel — September 10, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of…
InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System
IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States Tel Aviv, Israel — September 8,…
InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study
Tel Aviv, Israel — September 3, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid…
InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020
Tel Aviv, Israel — August 25, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment…
InspireMD Regains Compliance with NYSE AMERICAN Listing Standards
Tel Aviv, Israel — August 10, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment…
InspireMD Announces Second Quarter 2020 Financial Results
In the second quarter the Company was granted approval to market its CGuard™ MicroNet™ stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating…
InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate Update
Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET Tel Aviv, Israel — July 28, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™…
InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil
Tel Aviv, Israel — July 23, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid…
InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR
In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure Tel Aviv, Israel — June 25, 2020 – InspireMD, Inc….
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention
Results indicate that 12 months after carotid intervention the CGuard EPS MicroNet™-covered stent delivers sustained protection against postprocedural neurologic events Tel Aviv, Israel — June 10, 2020 – InspireMD,…
InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering
Tel Aviv, Israel— June 8, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery…
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
Tel Aviv, Israel— June 3, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery…
InspireMD Announces First Quarter 2020 Financial Results
First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets Management to host investor conference call today, May 12,…
InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12
InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12 Tel Aviv, Israel— May 5, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of…
InspireMD Announces Fourth Quarter and Year-End 2019 Financial Results
Robust CGuard™ EPS year-over-year revenue growth of 31% Management to host investor conference call today, March 10, at 8:30am ET Tel Aviv, Israel— March 10, 2010 – InspireMD, Inc. (NYSE…
InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10
Management to host conference call and webcast at 8:30am ET Tel Aviv, Israel— March 3, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS)…
InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020
Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS Tel Aviv, Israel — January 29, 2020 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention…
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany
Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented Tel Aviv, Israel— January 27, 2020 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention…
InspireMD Announces Strong Preliminary Fourth Quarter 2019 Revenue and Reports Inducement Award Under NYSE American Company Guide §711(a)
Tel Aviv, Israel — January 6, 2020 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid…
2019
InspireMD Announces Planned Leadership Transition
Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer Appointment adds significant medical technology commercialization experience to the InspireMD team Tel Aviv, Israel — December 10, 2019…
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major periprocedural, 30-day or one-year neurological complications…
InspireMD Announces Third Quarter 2019 Financial Results
Strong revenue driven by record orders of CGuard™ EPS Management to host investor conference call today, November 12, at 8:30am ET Tel Aviv, Israel— November 12, 2019 – InspireMD, Inc….
InspireMD to Report Third Quarter 2019 Financial Results and Provide Business Update on Tuesday, November 12
Management to host conference call and webcast at 8:30am ET Tel Aviv, Israel— November 5, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS)…
InspireMD, Inc. Announces Pricing of $5 Million Underwritten Public Offering
Tel Aviv, Israel— September 19, 2019 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery…
InspireMD Provides Business Update
Tel Aviv, Israel — September 9, 2019 – InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid…
InspireMD to Present at the HC Wainwright 21st Annual Global Investment Conference
Tel Aviv, Israel — September 9, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery…
InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency
Tel Aviv, Israel — August 9, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment…
InspireMD Announces Second Quarter 2019 Financial Results
U.S. Investigational Device Exemption (IDE) application submitted to FDA Company to host investor conference call today, August 6, at 8:00am ET Tel Aviv, Israel— August 6, 2019 – InspireMD, Inc….
InspireMD to Report Second Quarter 2019 Financial Results and Provide Business Update on Tuesday, August 6
Management to host conference call and webcast at 8am ET Tel Aviv, Israel— July 30, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS)…
InspireMD Announces First Quarter 2019 Financial Results
On-Track to Submit U.S. IDE expected in Mid-2019 Company to Host Investor Conference Call at 8:00am ET Tel Aviv, Israel— May 14, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer…
InspireMD to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 14
Management to host conference call and webcast at 8am ET Tel Aviv, Israel— May 7, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS)…
InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
Tel Aviv, Israel — April 4, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment…
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
Tel Aviv, Israel — April 3, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery…
InspireMD Announces 1-for-50 Reverse Stock Split
Tel Aviv, Israel— March 26, 2019 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD Provides Amended Disclosure
Tel Aviv, Israel — March 22, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment…
InspireMD Announces Fourth Quarter 2018 Financial Results
2018 CGuardTM EPS annual sales increased 55% compared to 2017 On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET Tel Aviv, Israel— February…
InspireMD to Report Fourth Quarter and Fiscal 2018 Financial Results and Provide Business Update on Tuesday, February 19
Conference Call Scheduled for 8am Eastern Time Tel Aviv, Israel— February 7, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention…
InspireMD Announces Presentation of Interim Data from Investigator-Initiated Study Comparing CGuard™ EPS with a Conventional Open-Cell Carotid Stent
CGuard™ EPS shows encouraging interim results verses a conventional carotid stent in absence of any adverse clinical events in the CGuard™ arm Data presented at the LINC 2019 Congress in…
InspireMD Announces Two Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2019
Cases demonstrate ease-of-use of CGuard™ EPS in two challenging clinical situations physicians face when treating carotid artery disease Tel Aviv, Israel — January 23, 2019 – InspireMD, Inc. (NYSE American:…
InspireMD Announces Results from Initial Clinical Study of The CGuard™ Embolic Prevention System (EPS) with SmartFitTM Technology
“Initial Clinical Study of the New CGuard™ EPS MicroNet™® Covered Carotid Stent: ‘One Size Fits All’” presented at the LINC 2019 Congress Tel Aviv, Israel— January 22, 2019 – InspireMD,…
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany
Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented Tel Aviv, Israel— January 18, 2019 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems…
InspireMD Announces the Distribution of CGuard™ Embolic Prevention System in South Africa
Growing awareness of CGuard™ EPS among treating physicians, and resulting demand, were key factors driving entry into the South African market Tel Aviv, Israel— January 14, 2019 – InspireMD,…
InspireMD Receives Noncompliance Notice from NYSE American
Tel Aviv, Israel— January 11, 2019 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…
2018
InspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems
Analysis includes clinical studies incorporating the Company’s MicroNet™™-covered stent, the CGuard™ Embolic Prevention System (EPS) Tel Aviv, Israel— December 18, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™…
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
Tel Aviv, Israel— November 29, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…
InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia Commercial Launch to Occur Immediately
Tel Aviv, Israel— November 28, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…
InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
Tel Aviv, Israel— November 13, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…
InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am ET…
InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
Conference Call Scheduled for 8am Eastern Time Tel Aviv, Israel— October 30, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention…
InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference
Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis Tel Aviv, Israel— September 27, 2018 – InspireMD, Inc. (NYSE American:…
InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico
Commercial Launch to Occur Immediately Tel Aviv, Israel— September 24, 2018 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of…
InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet™ Stent Jacket and Related Drug Eluting Technology
Patents further strengthen intellectual property surrounding Company’s lead commercial product, CGuard™ EPS InspireMD remains on track to submit an Investigational Device Exception (IDE) with FDA in mid-2019 Tel Aviv, Israel—…
InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City
Tel Aviv, Israel— September 4, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid…
InspireMD Reports 94% Increase in CGuard™ EPS RevenuesInspireMD Reports 94% Increase in CGuard™ EPS Revenuesfor the Second Quarter of 2018
Tel Aviv, Israel— August 6, 2018 – InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid…
InspireMD Schedules Second Quarter 2018 Earnings Conference Call
Tel Aviv – July 31, 2018 – InspireMD, Inc. (NYSE: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid…
InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
Tel Aviv, Israel— July 23, 2018 – InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of…
InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering
Tel Aviv, Israel— June 29, 2018 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing…
InspireMD’s CGuard™ EPS Featured at the SBHCI Congress in Brazil
Tel Aviv, Israel— June 20, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that CGuard™ EPS…
InspireMD’s CGuard™ EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery
Study results presented from 46 patients treated over two years with zero complications President of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of CGuard™ EPS…
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
Tel Aviv, Israel— June 11, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™…
InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS
Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months Tel Aviv, Israel— May 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention…
InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Ecuador
Tel Aviv, Israel— May 16, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received…
InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018
Tel Aviv, Israel— May 7, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the…
InspireMD Schedules First Quarter 2018 Earnings Conference Call
Tel Aviv – May 1, 2018 – InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will…
InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard™ EPS and MGuard Prime™ Products in Vietnam
Tel Aviv, Israel— April 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has received regulatory approval,…
InspireMD’s CGuard™ Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, PolandInspireMD’s CGuard™ Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland
Tel Aviv, Israel— April 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention…
InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million
Tel Aviv, Israel— April 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary unaudited sales results for…
InspireMD, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock
Tel Aviv, Israel— March 28, 2018 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an…
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
Tel Aviv, Israel— March 27, 2018 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it intends to…
InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Peru
Tel Aviv, Israel— March 27, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory…
InspireMD Announces First Patient Treated with CGuardTM EPS in India
Patient with severe stenosis, calcification and thrombosis successfully treated with CGuardTM EPS Tel Aviv, Israel— March 5, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) /…
InspireMD Announces Expansion of its Distribution Network
Tel Aviv, Israel— March 1, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an exclusive…
InspireMD, Inc. Announces Pricing of Public Offering of Common Stock
Tel Aviv, Israel— February 27, 2018 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an…
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
Tel Aviv, Israel— February 26, 2018 – InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it intends to…
InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard™ EPS in South Korea
Solvit Medical to fund all regulatory, registration and reimbursement submissions Tel Aviv, Israel— February 22, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies…
InspireMD Announces Commercial Launch and First Sales of CGuard™ EPS in India
Tel Aviv, Israel— February 20, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the commercial launch and first…
InspireMD Announces Fourth Quarter and Year-End 2017 Results; CGuard™ EPS Fourth Quarter Sales Increase 211% Versus Same Period Last year
Tel Aviv, Israel— February 14, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the…
InspireMD Announces 1-for-35 Reverse Stock Split
Tel Aviv, Israel— February 7, 2018 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD’s CGuard™ Embolic Prevention System Featured in a Second Live Case Transmission at LINC 2018 by Leading Interventional Cardiologists
Tel Aviv, Israel— January 31, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™…
InspireMD’s CGuard™ Embolic Prevention System Featured in Successful Live Case Transmissions at LINC 2018 by Leading Vascular Surgeons
Tel Aviv, Israel— January 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™…
InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Two Live Case Transmissions at LINC 2018
Tel Aviv, Israel— January 26, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic…
InspireMD Announces Publication of an Independent Imaging Study Highlighting the Advantages of CGuard™ EPS Compared to Another Next Generation Carotid Stent
Tel Aviv, Israel— January 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the publication of an independent…
InspireMD Projects 211% Increase in CGuard™ EPS Sales for the Fourth Quarter of 2017
Conference call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming shareholder meeting Tel Aviv, Israel— January 10, 2018 – InspireMD,…
InspireMD Schedules Conference Call to Discuss Recent Developments, Preliminary Sales Results and Proposals for Upcoming Shareholder Meeting
Tel Aviv—January 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call…
InspireMD Announces Regulatory Approval of CGuard™ EPS in India; Signs Agreement with Leading Indian Medical Device Distributor
Tel Aviv, Israel— January 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory…
2017
InspireMD’s CGuard™ Embolic Prevention System Once Again Featured in a Successful Live Clinical Case at Leading Industry Conference
Professor Pierfrancesco Veroux treated a patient with carotid artery disease using CGuard™ EPS Tel Aviv, Israel— December 18, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS)…
InspireMD’s CGuard™ EPS Demonstrates Improved Outcomes over Carotid Endarterectomy in 50 Patient Comparative Study; Preliminary Results Featured at the 7th Munich Vascular Conference 2017
Tel Aviv, Israel— December 7, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Professor Ralf Kolvenbach,…
InspireMD Announces Preliminary 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard™ EPS
No procedure or device related adverse events at 24 months Results presented at the 2017 VEITHsymposium in New York and ICI Meeting 2017 in Tel Aviv Tel Aviv, Israel— December…
InspireMD Announces Expansion of its Distribution Network for CGuard™ EPS in Australia, New Zealand and Vietnam
Tel Aviv, Israel— December 4, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed Diverse Devices…
InspireMD Announces Planned Recapitalization
Tel Aviv, Israel— November 29, 2017 – InspireMD, Inc. (NYSE MKT:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it entered into a…
InspireMD Announces Third Quarter 2017 Results; CGuard™ Revenue Increases 90% Versus Same Period Last year
Tel Aviv, Israel—November 7, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary results for the third quarter…
InspireMD Schedules Third Quarter 2017 Earnings Conference Call
Tel Aviv—November 1, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call…
InspireMD’s CGuard™ Carotid Embolic Prevention System Featured in Live Case at Cracow Vascular Summit 2017 in Poland
Prof. Waclaw Kuczmik performed successful case treating a patient with carotid artery disease with CGuard™ EPS in Katowice Clinical Hospital Tel Aviv, Israel – October 25, 2017 – InspireMD, Inc. (NYSE AMER:NSPR)…
New York Stock Exchange Accepts InspireMD’s Plan to Regain Compliance
Tel Aviv, Israel – October 24, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,…
InspireMD Announces Distribution Agreement for MGuard Prime™ in Chile
Tel Aviv, Israel—October 12, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with…
InspireMD Announces the Start of Patient Enrollment in an Investigator Initiated Trial of CGuard™ EPS in Russia
CGuard™ Embolic Prevention System (EPS) to be Randomized Against Abbott’s RX ACCULINK® Carotid Stent System Tel Aviv, Israel—October 9, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in Embolic Prevention Systems (EPS)…
InspireMD Postpones Special Meeting of Stockholders to October 27, 2017
Tel Aviv, Israel—October 4, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD Announces Distribution Agreement for CGuardTM EPS in Portugal
Tel Aviv, Israel—September 21, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City
Tel Aviv, Israel—September 6, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD Announces Distribution Agreement for CGuardTM EPS in Switzerland
Tel Aviv, Israel—August 25, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD Shares CGuardTM EPS Video Testimonials from European Key Opinion Leaders
Tel Aviv—August 22, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…
InspireMD Announces Notification of NYSE AMERICAN Listing Deficiency and Expectation to Regain Compliance
Tel Aviv– August 22, 2017 — InspireMD, Inc. (NYSE AMER: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today…
InspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017
Completes Transition to Local Distribution Network Across Europe CGuard Sales in European Countries Transitioned Back from Former Distributor Increase 122% Versus Q1 2017 Tel Aviv—August 8, 2017 – InspireMD, Inc. (NYSE MKT:NSPR)…
InspireMD Announces Publication of an Independent Clinical Review Authored by Leading U.S. and European Physicians Supporting Safety Advantages of Mesh-Covered Carotid Stents
Comprehensive Review of Clinical Trial Data Supports the Safety and Efficacy of Carotid Artery Stenting (CAS) Versus Carotid Endarterectomy (CEA) Mesh Covered Carotid Devices Transforming the CAS Field Highlights Key…
InspireMD’s CGuard™ Carotid Embolic Prevention System Featured at the SOLACI CACI Congress of Cardiology 2017 in Buenos Aires
CGuardTM EPS procedure recorded and broadcast to the entire congress Tel Aviv, Israel – August 3, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic…
InspireMD Schedules Second Quarter 2017 Earnings Conference Call
Tel Aviv—August 2, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today…
InspireMD Announces Completion of Transition from Exclusive European Distributor to InspireMD Managed Local Distribution Network
Agreements Completed with Leading Distributors in Austria and Belgium Tel Aviv, Israel—June 13, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS)…
InspireMD Announces Distribution Agreement for CGuard™ EPS in Taiwan
Tel Aviv, Israel—June 8, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD Announces the Publication of an Investigator Initiated Clinical Registry Reaffirming MGuardTM Prime as a Highly Effective Tool to Prevent Heart Damage in Coronary Artery Blockages with High Thrombotic Content
Study Entitled “Long term Outcomes of MGuard™ Stent Deployment in Saphenous Vein Grafts and Native Coronary Arteries: A Single Center Experience” Tel Aviv, Israel—June 7, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE…
InspireMD Announces Distribution Agreement for CGuardTM EPS in Poland
Tel Aviv, Israel—June 5, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD Announces Appointment of Paul Stuka as Chairman of the Board
Tel Aviv, Israel—June 2, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD to Present at the 6th Annual SeeThruEquity Microcap Investor Conference
NEW YORK, NY / ACCESSWIRE / May 31, 2017 / InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management…
InspireMD Announces First Two Patients in Hong Kong Successfully Treated with CGuard™ EPS
Tel Aviv, Israel—May 30, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced…
InspireMD’s CGuard™ Carotid Embolic Prevention System Featured in Live Case Transmission at EuroPCR 2017
Prof. Alberto Cremonesi’s team performed successful case treating a patient with carotid artery disease with CGuard™ EPS Tel Aviv, Israel – May 18, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE…
InspireMD Announces Publication of the IRON-GUARD Registry in EuroIntervention
Zero incidence of major adverse cardiovascular events including no major strokes BOSTON, MA—May 17, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention…
InspireMD Announces Distribution Agreements for CGuard™ EPS and MGuard Prime™ EPS in Peru and Ecuador
BOSTON, MA—May 15, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…
InspireMD Provides Business Update for the First Quarter of 2017
New Commercial Roll-Out of CGuard™ EPS on Schedule 84% Sequential Increase in Sales of CGuard™ Tel Aviv—May 9, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a…
InspireMD Schedules First Quarter 2017 Earnings Conference Call
Tel Aviv—May X, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that…
InspireMD Announces Distribution Agreement for CGuardTM EPS in Germany
Tel Aviv—May 1, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…
InspireMD Announces Distribution Agreement for CGuardTM EPS in the Netherlands
Tel Aviv—April 6, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…
InspireMD Announces Listing of Series B Warrants on the NYSE MKT
Tel Aviv—April 5, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the…
InspireMD Announces Distribution Agreement for CGuardTM in Turkey
Tel Aviv—April 4, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…
InspireMD Announces Commercial Launch of CGuard™ EPS in the Russian Federation at the ICCA Stroke Event In Moscow
BOSTON, MA—March 30, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the…
InspireMD’s CGuard™ Carotid Embolic Prevention System to be Featured at ICCA Stroke 2017 in Moscow, Russia
BOSTON, MA—March 23, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that its…
InspireMD Repays Term Note Ahead of Schedule
Tel Aviv—March 22, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that…
InspireMD Announces Distribution Agreement for CGuard™ EPS in Hong Kong
BOSTON, MA—March 21, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…
InspireMD Announces CGuardTM Distribution Agreement for the Russian Federation
Tel Aviv—March 20, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it…
InspireMD Reports Continued Progress in the Transition of European Sales and Distribution
Announces Agreements with Leading Distributors in the Baltic States BOSTON, MA—March 15, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS)…
InspireMD Announces Closing of Public Offering of Approximately $6.8 Million
BOSTON, MA – March 14, 2017 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,…
InspireMD Announces Pricing of Public Offering of up to $7.5 Million
BOSTON, MA – March 9, 2017 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,…
InspireMD Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
Transition from Exclusive Distribution Partner to Local Distributors and Internal Sales Strategy Validated by Strong Revenue Growth in Select Markets BOSTON, MA—February 16, 2017 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS)…
InspireMD’s CGuard™ Carotid Embolic Prevention System to be Featured at LINC 2017
PD Dr. Andrej Schmidt to perform live case transmission of carotid stent surgery utilizing CGuard™ BOSTON, MA– January 24, 2016 – InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) (“InspireMD” or the “Company”), a…
2016
InspireMD Announces Change in Presentation Time at LD Micro Main Event Conference to Tuesday, December 6 at 4:30PM PT
BOSTON, Mass. – December 5, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD to Present at LD Micro Main Event on December 6
BOSTON, Mass. – November 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016
– Company to Host Conference Call Today at 4:30pm ET – BOSTON, MA – November 14, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader…
InspireMD Announces CGuardTM Embolic Prevention System Commercialization Approval in Russia
BOSTON, MA – November 14, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced…
InspireMD to Report Third Quarter Financial Results on Monday, November 14, 2016
BOSTON, MA – November 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the third…
InspireMD CGuard™ Embolic Prevention System 12-Month Clinical Trial Data Further Validate Potential of CGuard™ to Improve Management of Carotid Artery Disease and Prevent Stroke
BOSTON, MA – November 1, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
Long-term Clinical Data on InspireMD’s CGuard™ Embolic Prevention System to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
Presentations Highlight Potential for CGuard™ to Improve Management of Carotid Artery Disease and Prevent Stroke BOSTON, MA – October 27, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or…
InspireMD Announces Appointment of Medical Device Industry Veteran Agustin Gago as Chief Commercial Officer
BOSTON, MA – October 26, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD Announces Independent Study Published in the Journal of Endovascular Therapy that Continues to Support the Clinical Benefit and Utility of the CGuard™ Embolic Prevention System
100% procedural success rate in a 30 patient study using the new CGuardTM Embolic Prevention System with no procedural related complications and zero strokes at 6-month follow up Companion Editorial…
InspireMD to Present at the Dawson James Securities 2nd Annual Growth Stock Conference on October 20
BOSTON, Mass. – October 13, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD Announces Adjustments to Shares Receivable Upon Warrant Exercise and Exercise Price Per Share
BOSTON, MA – October 6, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD Announces 1-for-25 Reverse Stock Split
BOSTON, MA – September 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD Appoints Thomas Kester to Board of Directors
BOSTON, MA – September 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2016
Company to Host Conference Call Today at 4:30pm ET BOSTON, MA – August 9, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic…
InspireMD to Report Second Quarter Financial Results on Tuesday, August 9, 2016
BOSTON, MA – August 2, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the…
InspireMD Announces Listing of Warrants on the NYSE MKT
BOSTON, MA – August 1, 2016 — InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies,…
InspireMD Regains Compliance with NYSE MKT Listing Standards
BOSTON, MA – July 21, 2016 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Announces Closing of Public Offering of Approximately $14.6 Million
BOSTON, MA – July 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Announces Pricing of Public Offering of Approximately $14.6 Million
BOSTON, MA – June 30, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Announces Amendment to Loan & Security Agreement with Hercules Capital
Principal Payments Deferred, Assisting Cash Management Programs BOSTON, MA – June 14, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems…
InspireMD Names Dr. James Barry as President and CEO
Medical Device Veteran Brings Broad Industry Experience in Pioneering Technologies BOSTON, MA – June 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic…
InspireMD’s CGuardTM Highlighted at the Late-Breaking Clinical Trial Session at the EuroPCR 2016 Conference
BOSTON, MA – May 17, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016
BOSTON, MA – May 10, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Announces Late-Breaking Trial Presentation on CGuardTM Embolic Prevention System at EuroPCR 2016 Conference
BOSTON, MA – May 5, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Receives Audit Opinion with Going Concern Explanation
BOSTON, MA – March 31, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
BOSTON, MA – March 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD Announces Closing of Public Offering
BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of an underwritten public offering of…
InspireMD Announces Closing of Private Placement to Certain Officers and Directors
BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of its private placement of 1,033,051…
InspireMD Announces Pricing of Public Offering
BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the pricing of an underwritten…
InspireMD Announces Private Placement to Certain Officers and Directors
BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced a private placement (the “Private…
InspireMD Announces Proposed Public Offering of Common Stock and Warrants
BOSTON, MA – March 15, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced that it intends to offer and sell, subject…
InspireMD Aligns Operations and Leadership Team, Appoints Isaac Blech as Vice Chairman of the Board
Enhances Commercial and Development Execution Reduces Operating Cost Structure Strengthens Board of Directors BOSTON, MA – January 22, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”),…
2015
InspireMD Receives EU Regulatory Approval for Additional Supplier of CGuardTM Delivery Catheters
BOSTON, MA – December 2, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…
InspireMD Announces Positive Twelve Month Follow-Up CARENET Trial Data at VEITH Symposium 2015
BOSTON, MA – November 20, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…
InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2015
BOSTON, MA – November 10, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today…
InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2015 on Tuesday, November 10th
BOSTON, MA – November 2, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…
InspireMD Announces CGuardTM Approval in Argentina
CGuardTM Clinical Data Presented at TCT 2015 Carotid Scientific Sessions BOSTON, MA – October 19, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in…
InspireMD to Present at Dawson James Securities Growth Stock Conference
BOSTON, MA – September 8, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…
InspireMD Announces CGuardTM Approval in Colombia
BOSTON, MA – October 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…
InspireMD Announces One-for-Ten Reverse Stock Split
BOSTON, MA – October 1, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…
InspireMD Announces Full Market Launch of CGuardTM Distributed by Penumbra at CIRSE Annual Congress
BOSTON, MA – September 28, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced…
InspireMD Announces the Issuance of Two United States Patents
Continued Focus on Intellectual Property Results in Continued Portfolio Expansion BOSTON, MA – September 17, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic…
InspireMD Announces Allowance of US Patent Claims
Continues to Strengthen and Broaden Intellectual Property Portfolio BOSTON, MA – September 9, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”) a leader in embolic prevention…
InspireMD to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
BOSTON, MA – September 1, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) a leader in stent embolic prevention systems (“EPS”) and thrombus management technologies, today announced that its Chief Executive…
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2015
BOSTON, MA – August 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic prevention systems (“EPS”), today announced its financial and operating…
InspireMD Announces Distribution Partnership of its CGuardTM Embolic Prevention System with Penumbra, Inc.
Accelerates InspireMD’s Access into Key Geographic & Specialty Markets Enables CGuardTM to be Commercialized as Part of a Total Systems Solution BOSTON, MA – August 5, 2015 – InspireMD, Inc….
InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2015 on Wednesday, August 5th
BOSTON, MA – July 14, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, announced today that it will release its full…
InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award
Recognized for Successful Introduction of New and Innovative Products, with Emphasis on Quality and Customer Value BOSTON, MA – July 7, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the…
InspireMD’s CGuard™ Highlighted at Clinical Presentation at EuroPCR 2015 Conference
PARADIGM Evaluation Reports CGuard™ Favorable Outcomes in All-Comer Carotid Disease Population BOSTON, MA – May 12, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in…
InspireMD Announces Clinical Presentations on CGuard™ and MGuard™ Systems with MicroNet™ Technology at EuroPCR 2015 Conference
Clinical Presentations Highlight Carotid and Coronary Applications of InspireMD’s Proprietary MicroNet™ Technology BOSTON, MA – May 12, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader…
InspireMD Reports Financial Results for the First Quarter Ended March 31, 2015
BOSTON, MA – May 11, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its financial and operating results…
InspireMD Announces MGuard™ Prime Approval in Brazil
BOSTON, MA – April 27, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced it received approval to commercialize MGuard™ Prime™ with MicroNet™ technology in Brazil….
InspireMD Announces Completion of Sales Restructuring Program
BOSTON, MA – April 15, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced the completion of its sales…
InspireMD Plan of Compliance Accepted by NYSE MKT
BOSTON, MA – March 16, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), announced today that the New York Stock…
InspireMD Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
BOSTON, MA – March 12, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems (“EPS”), today announced its financial and operating…
InspireMD Announces Closing of Public Offering for Approximately $13.7 Million
BOSTON, MA – March 9, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced the closing of its offering…
InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th
BOSTON, MA – March 6, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), announced today that it will release its…
InspireMD Announces Proposed Public Offering of Common Stock and Warrants
BOSTON, MA – March 4, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it intends to offer…
InspireMD Announces Public Offering for Approximately $13.5 Million
BOSTON, MA – March 3, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it has entered into…
InspireMD to Present at the Cowen and Company 35th Annual Healthcare Conference
Presentation to be Webcast on March 3, 2015 at 10:40 a.m. ET BOSTON, MA – February 26, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader…
InspireMD Receives CE Mark Approval for Its New CGuard RX and Announces Positive Six Month Follow-Up CARENET Trial Data at LINC 2015
The New CGuardTM RX Rapid Exchange System Receives CE Mark Approval Six-Month Ultrasound Analysis Confirms Widely Patent Internal and External Carotid Arteries When Compared to Conventional Carotid Stents BOSTON,…
InspireMD Announces Notification of NYSE MKT Listing Deficiency
BOSTON, MA – January 21, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced the receipt of a notice…
InspireMD to Announce Positive Six Month Results from the CGuardTM CARENET Trial at LINC 2015
CGuardTM All Comer Data Continues to Show Excellent Clinical Benefits of the MicroNet™TM Covered Technology Six-Month Ultrasound Analysis is Indicative of Patent Carotid Arteries Without Restenosis Concern When Compared to…
InspireMD Pre-Announces a Fourth Quarter 2014 Revenue Increase of 200% Over the Third Quarter of 2014 and Provides Update on Corporate and Commercial Strategies
Near-term Focus On Carotid and DES Products, Streamlined Operations BOSTON, MA – January 5, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic…
2014
InspireMD Announces Important Clinical Data from MASTER and CARENET Trials
MASTER I and MASTER II Pooled Data Show Statistically Significant Mortality Benefit CARENET 30 Day DW-MRI Data Demonstrates Significant Reduction in New Ischemic Ipsilateral Lesions BOSTON, MA – December 15, 2014…
InspireMD Reports Financial Results for the Third Quarter ended September 30, 2014
Master II 30 day data to be presented December 15th at the ICI Meeting 2014, Tel-Aviv Announced first pre-clinical implant with partner DES platform BOSTON, MA – November 12, 2014…
InspireMD Completes $8.1 Million Registered Direct Offering
BOSTON, MA – November 7, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced the closing of its registered direct offering…
InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2014 on Wednesday, November 12th
BOSTON, MA – November 5, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems, announced today that it will release its…
InspireMD Announces Registered Direct Offering for Approximately $8 Million
BOSTON, MA – November 4, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced that it has entered into a definitive…
InspireMD Investigational Device Exemption (IDE) Amendment Approved by the FDA
Validation of manufacturing process changes for the MGuard Prime EPS BOSTON, MA – October 29, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in Embolic Protection Systems (EPS),…
InspireMD Resumes MGuard Prime Sales and Prioritizes DES and Carotid – New Product Programs
MGuard Prime commercial re-launch complete in direct markets Drug Eluting Stent (DES) program advances in development with partners — MASTER II trial to suspend enrollment to support DES and…
InspireMD Announces Initial Commercial Sales of the CGuard™ EPS
BOSTON, MA – October 1, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has recorded the first commercial sales…
InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard™ CARENET Trial on September 24th
CARENET Trial data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, September 16, 2014,showed 0% MACE at 30 Days BOSTON, MA – September 18, 2014 — InspireMD, Inc.(NYSE MKT:…
InspireMD Announces Positive Results from CGuard™ CARENET Trial with 0% MACE reported at 30 Days
Achieved Primary 30 Day Endpoint Patients in CARENET Trial had significantly lower incidence of new ischemic lesions compared to historical control groups of non-mesh covered carotid stents BOSTON,…
InspireMD to Present at the Aegis Healthcare and Technology Conference
BOSTON, MA – September 03, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that its Chief Financial Officer, Craig…
InspireMD to Announce Results of CGuard™ CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies
Results will be announced on Tuesday, September 16in Washington, D.C. BOSTON, MA – August 11, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection…
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014
BOSTON, MA – July 23, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its financial and operating results for…
InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2014 on Wednesday, July 23rd
BOSTON, MA – July 17, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, announced today that it will release its financial…
InspireMD Appoints Dr. James Barry as Chief Operating Officer
Strengthens Leadership Team with Addition of Experienced Medical Device Executive BOSTON, MA – July 15, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic…
InspireMD Announces Successful Completion of CGuard™ CARENET (CARotid Embolic protection study using MicroNet™) Trial
100% procedural success rate achieved in first multi-specialty clinical experience BOSTON, MA – July 8, 2014 — InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection…
InspireMD Selected for Inclusion in the Russell Microcap Index
BOSTON, MA – July 1, 2014 — InspireMD Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced that it has been selected to join…
InspireMD Receives European Regulatory Approval to Resume Manufacturing and Distribution of MGuardTM Prime EPS
BOSTON, MA – June 23, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it received European regulatory approval to resume…
InspireMD to Present at the 9th Annual JMP Securities Healthcare Conference
BOSTON, MA – June 18, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the 9th Annual…
InspireMD Reports Financial Results for the First Quarter Ended March 31, 2014
BOSTON, MA – May 7, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced financial and operating results for…
InspireMD Announces Positive Results from iMOS Prime Registry for the MGuard Prime EPS
Study of 97 patients resulted in zero mortalities in STEMI patients as of 30-day follow up Results to be presented at EuroPCR meeting in Paris on Thursday, May 22nd at…
InspireMD Announces Voluntary Field Action for MGuardTM Prime EPS
BOSTON, MA – April 30, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has initiated a Voluntary Field Action…
InspireMD to Report Financial Results for Quarter Ended March 31, 2014 on Wednesday, May 7th
BOSTON, MA – April 30, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will release its financial results…
InspireMD Announces First Patient Enrolled Into New CGuard™ CARENET (CARotid Embolic protection study using MicroNet™) Clinical Trial
Proven Embolic Protection System Expands to Treat Carotid Artery Disease BOSTON, MA – March 19, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems,…
InspireMD to Present at the 26th Annual ROTH Conference
BOSTON, MA – March 6, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the 26th Annual…
InspireMD to Present at the Cowen & Company 34th Annual Health Care Conference
BOSTON, MA – February 27, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo, will be presenting at the Cowen &…
InspireMD Reports Financial Results for the Quarter and Six Month Period Ended December 31, 2013
BOSTON, MA – February 26, 2014 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems, today announced financial and operating results for the…
InspireMD to Report Financial Results for Six Month Period Ended December 31, 2013 on Wednesday, February 26, 2014
BOSTON, MA – February 18, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will release its financial results…
InspireMD Reports Successful Implantation of the New CGuardTM Carotid Embolic System with MicroNet™TM Technology
Acclaimed Embolic Protection System Expands to Treat Carotid Artery Disease BOSTON, MA – February 5, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems,…
2013
InspireMD to Present at the 24th Annual Oppenheimer & Co. Healthcare Conference in New York City on December 11th
BOSTON, MA – December 3, 2013 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), today announced that its CEO, Alan Milinazzo will be presenting at the 24th Annual…
InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
Company Strengthens Leadership Team with Addition of Experienced Global Sales Executive BOSTON, MA – December 2, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader…
InspireMD Announces Upcoming Investor Event in Israel
Company to Host Investor Event on December 2, 2013 at 5:00 p.m. IST BOSTON, MA – November 19, 2013 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR),…
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
BOSTON, MA – November 11, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, today announced financial results for the quarter ended…
InspireMD’s MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
Company to Host Conference Call Tomorrow at 5:30 a.m. PT / 8:30 a.m. ET BOSTON, MA – October 29, 2013 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a…
InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
BOSTON, MA – October 28, 2013 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will host a conference call…
InspireMD Files At-the-Market Offering and Shelf Registration Statement
BOSTON, MA – October 24, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it has filed a $75…
InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan
Funding for expansion of clinical trial and product development strategies BOSTON, MA – October 24, 2013 – InspireMD Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in…
InspireMD to Ring Opening Bell at New York Stock Exchange on Thursday, October 24th
BOSTON, MA – October 23, 2013 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection stents, announced today that it will ring the Opening Bell…
CMS Announcement
On October 11, 2023, CMS issued a National Coverage Determination (NCD) for the coverage of Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting. This expanded coverage profoundly increases the available market for endovascular procedures, extending coverage for carotid stenting to both symptomatic and asymptomatic patients regardless of surgical risk; only symptomatic patients at high surgical risk were covered by the previous NCD.
Follow Us |
   |
 |
|
For more information, please provide your email and someone will contact you shortly
|